Clinical Oncology News | Dose-Dense Regimen Does Not Improve R-CHOP for DLBCL Clinical Oncology News The addition of rituximab (Rituxan, Genentech) to the regimen (i.e., R-CHOP) was found to improve cure rates by 10% to 15%. Researchers from the United Kingdom, headed by David Cunningham, MD, sought to compare R-CHOP-14 with R-CHOP-21 to ... |
